Full Generic Medicine Info
Dosage/Direction for Use

Acute migraine attacks
Adult: Initially, 1-2.5 mg, dose may be repeated after 4 hr if symptoms recur (2nd dose should not be taken for same attack). Max: 5 mg daily.
Renal impairment: Mild to moderate: Initially, 1 mg. Max 2.5 mg daily.
CrCl (ml/min)Dosage Recommendation
Hepatic impairment: Mild to moderate (Child-Pugh class A or B): Initially, 1 mg. Max 2.5 mg daily. Severe (Child-Pugh class C): Contraindicated.
May be taken with or without food.
Hypersensitivity. Coronary artery disease (e.g. angina pectoris, silent ischaemia, MI), coronary artery vasospasm, Prinzmetal's angina, uncontrolled HTN, cerebrovascular syndromes (e.g. stroke, TIA), hemiplegic or basilar migraine, Wolff-Parkinson-White syndrome, peripheral vascular disease, ischemic bowel disease. Severe renal (CrCl <15 mL/min) and hepatic (Child-Pugh class C) impairment. Concomitant use w/ ergot derivatives and 5-HT1 receptor agonists.
Special Precautions
Patient w/ multiple CV risk factors. Not intended for cluster headache and for the prevention of migraine attacks. Mild to moderate renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, weakness, or drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Assess clear diagnosis of migraine and neurological conditions prior to initiation of therapy. Perform periodic CV evaluation for patients w/ risk factors for coronary artery disease who are receiving intermittent long-term therapy. Monitor ECG, BP, signs and symptoms of withdrawal, serotonin syndrome, angina, hypersensitivity reactions, and headache severity.
Adverse Reactions
Significant: Chest pain/tightness, peripheral vascular ischaemia, GI vascular ischaemia/infarction, splenic infarction, Raynauld's syndrome, transient and permanent blindness, partial loss of vision, recurrent/rebound headaches, withdrawal syndrome; hypertensive crisis, medication-overuse headache (MOH). Nervous: Tingling sensation, paraesthesia, dizziness, somnolence, drowsiness, malaise, fatigue, heaviness sensation, hot/cold flushes, dizziness, vertigo, weakness. CV: Bradycardia, palpitations. GI: Nausea, vomiting, xerostomia. Resp: Pharynx constriction. Musculoskeletal: Neck pain. Ophthalmologic: Photophobia.
Potentially Fatal: Acute MI, coronary artery vasospasm, transient ischaemia, ventricular tachycardia/fibrillation, cerebral or subarachnoid haemorrhage, stroke, hypersensitivity reactions (e.g. angioedema).
Symptoms: Increase in BP, light-headedness, neck tension, tiredness, loss of coordination, ECG changes. Management: Supportive treatment. Monitor patient for at least 24 hr.
Food Interaction
May cause undesirable adverse effects w/ St John's wort.
Naratriptan is a selective serotonin (5-HT1B/1D) receptor agonist in intracranial blood vessels, which causes vasoconstriction and reduction in oedema formation in the meninges thus alleviating migraine. It is also thought to inhibit trigeminal nerve activity.
Absorption: Rapidly and well absorbed from the GI tract. Bioavailability: Approx 70%. Time to peak plasma concentration: 2-3 hr.
Distribution: Volume of distribution: 170 L. Plasma protein binding: Approx 29%.
Metabolism: Metabolised in the liver by CYP enzymes into inactive metabolites.
Excretion: Via urine (50% as unchanged drug, 30% as inactive metabolites). Elimination half-life: 6 hr.
Oral: Store between 20-25°C.
CIMS Class
Antimigraine Preparations
ATC Classification
N02CC02 - naratriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Disclaimer: This information is independently developed by CIMS based on naratriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in